Atrae, Inc. Logo

Atrae, Inc.

Develops People Tech solutions for HR, including big data job sites and organizational analytics.

6194 | T

Overview

Corporate Details

ISIN(s):
JP3121890002
LEI:
Country:
Japan
Address:
港区麻布十番1−10−10
Sector:
Mining and quarrying
Industry:
Mining of non-ferrous metal ores

Description

Atrae, Inc. is a technology company that defines its business domain as “People Tech,” with a mission to create services that expand human potential. The company develops and manages IT solutions primarily for the Human Resources sector. Its portfolio includes contingent fee-based job websites that leverage big data to connect talent with opportunities. A key product is Wevox, a platform designed to analyze organizational health and improve corporate value, which is also offered through a joint venture with SMBC Group. Atrae also operates in the "Sports Tech" segment, consistently aiming to build businesses that attract people worldwide.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-10-14 09:46
Transaction in Own Shares
自己株券買付状況報告書(法24条の6第1項に基づくもの)
Japanese 26.2 KB
2025-09-12 08:55
Transaction in Own Shares
自己株券買付状況報告書(法24条の6第1項に基づくもの)
Japanese 22.8 KB
2025-05-14 08:05
Interim Report
半期報告書-第22期(2024/10/01-2025/09/30)
Japanese 166.2 KB
2025-05-14 08:05
Report Publication Announcement
確認書
Japanese 8.0 KB
2025-04-14 09:06
Transaction in Own Shares
自己株券買付状況報告書(法24条の6第1項に基づくもの)
Japanese 23.8 KB
2025-03-13 08:50
Transaction in Own Shares
自己株券買付状況報告書(法24条の6第1項に基づくもの)
Japanese 22.7 KB
2025-02-03 08:20
Share Issue/Capital Change
訂正臨時報告書
Japanese 37.7 KB
2025-01-14 07:16
Regulatory News Service
臨時報告書
Japanese 39.6 KB
2025-01-14 07:14
Regulatory News Service
臨時報告書
Japanese 29.8 KB
2024-12-23 01:58
Post-Annual General Meeting Information
臨時報告書
Japanese 21.8 KB
2024-12-19 02:05
Regulatory News Service
確認書
Japanese 8.0 KB
2024-12-19 02:04
Regulatory News Service
内部統制報告書-第21期(2023/10/01-2024/09/30)
Japanese 21.6 KB
2024-12-19 02:03
Annual Report
有価証券報告書-第21期(2023/10/01-2024/09/30)
Japanese 985.6 KB
2024-11-14 08:08
Earnings Release
臨時報告書
Japanese 18.2 KB
2024-10-11 08:52
Transaction in Own Shares
自己株券買付状況報告書(法24条の6第1項に基づくもの)
Japanese 23.5 KB

Automate Your Workflow. Get a real-time feed of all Atrae, Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Atrae, Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Atrae, Inc. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Noile-Immune Biotech Inc. Logo
Developing PRIME technology-enhanced CAR-T cell immunotherapies for treating solid tumors.
Japan
4893
NRGene Technologies Ltd. Logo
AI-powered genomic analysis software to accelerate and optimize plant and animal breeding.
Israel
NRGN
Nuvectis Pharma, Inc. Logo
Clinical-stage biopharma developing precision medicines for serious oncological conditions.
United States of America
NVCT
Nykode Therapeutics ASA Logo
Developing novel immunotherapies and vaccines for cancer with its antigen-targeting platform.
Norway
NYKD
Ocugen, Inc. Logo
Develops gene/cell therapies and vaccines, specializing in blindness and public health.
United States of America
OCGN
Oculis Holding AG Logo
Clinical-stage biopharma developing non-invasive eye drops for sight-threatening diseases.
Switzerland
OCS
OKYO Pharma Ltd Logo
Biopharma developing novel drugs for inflammatory eye diseases and neuropathic corneal pain.
United States of America
OKYO
OLIPASS CORPORATION Logo
Biotech firm developing RNA therapeutics for diseases with its proprietary OPNA platform.
South Korea
244460
A technology platform for pharma/biotech to discover therapeutic antibodies via transgenic animals.
United States of America
OABIW
Oncocross Co.,Ltd. Logo
AI-powered biotech accelerating drug development for cancer and rare diseases.
South Korea
382150

Talk to a Data Expert

Have a question? We'll get back to you promptly.